Cargando…
A prospective feasibility study evaluating the 5x-multiplier to standardize discharge prescriptions in cancer surgery patients
BACKGROUND: We designed a prospective feasibility study to assess the 5x-multiplier (5x) calculation (eg, 3 pills in last 24 hours × 5 = 15) to standardize discharge opioid prescriptions compared to usual care. METHODS: Faculty-based surgical teams volunteered for either 5x or usual care arms. Patie...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9161107/ https://www.ncbi.nlm.nih.gov/pubmed/35663797 http://dx.doi.org/10.1016/j.sopen.2022.04.004 |
_version_ | 1784719416592695296 |
---|---|
author | DiPeri, Timothy P. Newhook, Timothy E. Day, Ryan W. Chiang, Yi-Ju Dewhurst, Whitney L. Arvide, Elsa M. Bruno, Morgan L. Scally, Christopher P. Roland, Christina L. Katz, Matthew H.G. Vauthey, Jean-Nicolas Chang, George J. Badgwell, Brian D. Perrier, Nancy D. Grubbs, Elizabeth G. Lee, Jeffrey E. Tzeng, Ching-Wei D. |
author_facet | DiPeri, Timothy P. Newhook, Timothy E. Day, Ryan W. Chiang, Yi-Ju Dewhurst, Whitney L. Arvide, Elsa M. Bruno, Morgan L. Scally, Christopher P. Roland, Christina L. Katz, Matthew H.G. Vauthey, Jean-Nicolas Chang, George J. Badgwell, Brian D. Perrier, Nancy D. Grubbs, Elizabeth G. Lee, Jeffrey E. Tzeng, Ching-Wei D. |
author_sort | DiPeri, Timothy P. |
collection | PubMed |
description | BACKGROUND: We designed a prospective feasibility study to assess the 5x-multiplier (5x) calculation (eg, 3 pills in last 24 hours × 5 = 15) to standardize discharge opioid prescriptions compared to usual care. METHODS: Faculty-based surgical teams volunteered for either 5x or usual care arms. Patients undergoing inpatient (≥ 48 hours) surgery and discharged by surgical teams were included. The primary end point was discharge oral morphine equivalents. Secondary end points were opioid-free discharges and 30-day refill rates. RESULTS: Median last 24-hour oral morphine equivalents was similar between arms (7.5 mg 5x vs 10 mg usual care, P = .830). Median discharge oral morphine equivalents were less in the 5x arm (50 mg 5x vs 75 mg usual care, P < .001). Opioid-free discharges included 33.5% 5x vs 18.0% usual care arm patients (P < .001). Thirty-day refill rates were similar (15.3% 5x vs 16.5% usual care, P = .742). CONCLUSION: The 5x-multiplier was associated with reduced opioid prescriptions without increased refills and can be feasibly implemented across a diverse surgical practice. |
format | Online Article Text |
id | pubmed-9161107 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-91611072022-06-03 A prospective feasibility study evaluating the 5x-multiplier to standardize discharge prescriptions in cancer surgery patients DiPeri, Timothy P. Newhook, Timothy E. Day, Ryan W. Chiang, Yi-Ju Dewhurst, Whitney L. Arvide, Elsa M. Bruno, Morgan L. Scally, Christopher P. Roland, Christina L. Katz, Matthew H.G. Vauthey, Jean-Nicolas Chang, George J. Badgwell, Brian D. Perrier, Nancy D. Grubbs, Elizabeth G. Lee, Jeffrey E. Tzeng, Ching-Wei D. Surg Open Sci Original Article BACKGROUND: We designed a prospective feasibility study to assess the 5x-multiplier (5x) calculation (eg, 3 pills in last 24 hours × 5 = 15) to standardize discharge opioid prescriptions compared to usual care. METHODS: Faculty-based surgical teams volunteered for either 5x or usual care arms. Patients undergoing inpatient (≥ 48 hours) surgery and discharged by surgical teams were included. The primary end point was discharge oral morphine equivalents. Secondary end points were opioid-free discharges and 30-day refill rates. RESULTS: Median last 24-hour oral morphine equivalents was similar between arms (7.5 mg 5x vs 10 mg usual care, P = .830). Median discharge oral morphine equivalents were less in the 5x arm (50 mg 5x vs 75 mg usual care, P < .001). Opioid-free discharges included 33.5% 5x vs 18.0% usual care arm patients (P < .001). Thirty-day refill rates were similar (15.3% 5x vs 16.5% usual care, P = .742). CONCLUSION: The 5x-multiplier was associated with reduced opioid prescriptions without increased refills and can be feasibly implemented across a diverse surgical practice. Elsevier 2022-04-25 /pmc/articles/PMC9161107/ /pubmed/35663797 http://dx.doi.org/10.1016/j.sopen.2022.04.004 Text en © 2022 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Original Article DiPeri, Timothy P. Newhook, Timothy E. Day, Ryan W. Chiang, Yi-Ju Dewhurst, Whitney L. Arvide, Elsa M. Bruno, Morgan L. Scally, Christopher P. Roland, Christina L. Katz, Matthew H.G. Vauthey, Jean-Nicolas Chang, George J. Badgwell, Brian D. Perrier, Nancy D. Grubbs, Elizabeth G. Lee, Jeffrey E. Tzeng, Ching-Wei D. A prospective feasibility study evaluating the 5x-multiplier to standardize discharge prescriptions in cancer surgery patients |
title | A prospective feasibility study evaluating the 5x-multiplier to standardize discharge prescriptions in cancer surgery patients |
title_full | A prospective feasibility study evaluating the 5x-multiplier to standardize discharge prescriptions in cancer surgery patients |
title_fullStr | A prospective feasibility study evaluating the 5x-multiplier to standardize discharge prescriptions in cancer surgery patients |
title_full_unstemmed | A prospective feasibility study evaluating the 5x-multiplier to standardize discharge prescriptions in cancer surgery patients |
title_short | A prospective feasibility study evaluating the 5x-multiplier to standardize discharge prescriptions in cancer surgery patients |
title_sort | prospective feasibility study evaluating the 5x-multiplier to standardize discharge prescriptions in cancer surgery patients |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9161107/ https://www.ncbi.nlm.nih.gov/pubmed/35663797 http://dx.doi.org/10.1016/j.sopen.2022.04.004 |
work_keys_str_mv | AT diperitimothyp aprospectivefeasibilitystudyevaluatingthe5xmultipliertostandardizedischargeprescriptionsincancersurgerypatients AT newhooktimothye aprospectivefeasibilitystudyevaluatingthe5xmultipliertostandardizedischargeprescriptionsincancersurgerypatients AT dayryanw aprospectivefeasibilitystudyevaluatingthe5xmultipliertostandardizedischargeprescriptionsincancersurgerypatients AT chiangyiju aprospectivefeasibilitystudyevaluatingthe5xmultipliertostandardizedischargeprescriptionsincancersurgerypatients AT dewhurstwhitneyl aprospectivefeasibilitystudyevaluatingthe5xmultipliertostandardizedischargeprescriptionsincancersurgerypatients AT arvideelsam aprospectivefeasibilitystudyevaluatingthe5xmultipliertostandardizedischargeprescriptionsincancersurgerypatients AT brunomorganl aprospectivefeasibilitystudyevaluatingthe5xmultipliertostandardizedischargeprescriptionsincancersurgerypatients AT scallychristopherp aprospectivefeasibilitystudyevaluatingthe5xmultipliertostandardizedischargeprescriptionsincancersurgerypatients AT rolandchristinal aprospectivefeasibilitystudyevaluatingthe5xmultipliertostandardizedischargeprescriptionsincancersurgerypatients AT katzmatthewhg aprospectivefeasibilitystudyevaluatingthe5xmultipliertostandardizedischargeprescriptionsincancersurgerypatients AT vautheyjeannicolas aprospectivefeasibilitystudyevaluatingthe5xmultipliertostandardizedischargeprescriptionsincancersurgerypatients AT changgeorgej aprospectivefeasibilitystudyevaluatingthe5xmultipliertostandardizedischargeprescriptionsincancersurgerypatients AT badgwellbriand aprospectivefeasibilitystudyevaluatingthe5xmultipliertostandardizedischargeprescriptionsincancersurgerypatients AT perriernancyd aprospectivefeasibilitystudyevaluatingthe5xmultipliertostandardizedischargeprescriptionsincancersurgerypatients AT grubbselizabethg aprospectivefeasibilitystudyevaluatingthe5xmultipliertostandardizedischargeprescriptionsincancersurgerypatients AT leejeffreye aprospectivefeasibilitystudyevaluatingthe5xmultipliertostandardizedischargeprescriptionsincancersurgerypatients AT tzengchingweid aprospectivefeasibilitystudyevaluatingthe5xmultipliertostandardizedischargeprescriptionsincancersurgerypatients AT aprospectivefeasibilitystudyevaluatingthe5xmultipliertostandardizedischargeprescriptionsincancersurgerypatients AT diperitimothyp prospectivefeasibilitystudyevaluatingthe5xmultipliertostandardizedischargeprescriptionsincancersurgerypatients AT newhooktimothye prospectivefeasibilitystudyevaluatingthe5xmultipliertostandardizedischargeprescriptionsincancersurgerypatients AT dayryanw prospectivefeasibilitystudyevaluatingthe5xmultipliertostandardizedischargeprescriptionsincancersurgerypatients AT chiangyiju prospectivefeasibilitystudyevaluatingthe5xmultipliertostandardizedischargeprescriptionsincancersurgerypatients AT dewhurstwhitneyl prospectivefeasibilitystudyevaluatingthe5xmultipliertostandardizedischargeprescriptionsincancersurgerypatients AT arvideelsam prospectivefeasibilitystudyevaluatingthe5xmultipliertostandardizedischargeprescriptionsincancersurgerypatients AT brunomorganl prospectivefeasibilitystudyevaluatingthe5xmultipliertostandardizedischargeprescriptionsincancersurgerypatients AT scallychristopherp prospectivefeasibilitystudyevaluatingthe5xmultipliertostandardizedischargeprescriptionsincancersurgerypatients AT rolandchristinal prospectivefeasibilitystudyevaluatingthe5xmultipliertostandardizedischargeprescriptionsincancersurgerypatients AT katzmatthewhg prospectivefeasibilitystudyevaluatingthe5xmultipliertostandardizedischargeprescriptionsincancersurgerypatients AT vautheyjeannicolas prospectivefeasibilitystudyevaluatingthe5xmultipliertostandardizedischargeprescriptionsincancersurgerypatients AT changgeorgej prospectivefeasibilitystudyevaluatingthe5xmultipliertostandardizedischargeprescriptionsincancersurgerypatients AT badgwellbriand prospectivefeasibilitystudyevaluatingthe5xmultipliertostandardizedischargeprescriptionsincancersurgerypatients AT perriernancyd prospectivefeasibilitystudyevaluatingthe5xmultipliertostandardizedischargeprescriptionsincancersurgerypatients AT grubbselizabethg prospectivefeasibilitystudyevaluatingthe5xmultipliertostandardizedischargeprescriptionsincancersurgerypatients AT leejeffreye prospectivefeasibilitystudyevaluatingthe5xmultipliertostandardizedischargeprescriptionsincancersurgerypatients AT tzengchingweid prospectivefeasibilitystudyevaluatingthe5xmultipliertostandardizedischargeprescriptionsincancersurgerypatients AT prospectivefeasibilitystudyevaluatingthe5xmultipliertostandardizedischargeprescriptionsincancersurgerypatients |